Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors

Pathology and Oncology Research

Volumn 5, Issue 1, 1999, Pages 21-27

  Rathore, Annapurna ^a   Kamarajan, Pacchapam ^a   Mathur, Meera ^a   Sinha, Subrata ^a   Sarkar, Chitra ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Astrocytic tumors; Immunochemistry; p53; pRb; Survival

Indexed keywords

PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SCHOOL CHILD;

EID: 0033104032     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1053/paor.1999.0021     Document Type: Article

References (32)

1. 1. Aka K, Barner JM, Bondy ML, et al: Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reactions. J Neurooncol 16:125-133, 1993.
2. 2. Bourne JA: Handbook of immunoperoxidase staining methods. Dako corporation, USA, 1983, p17.
3. 3. Buckovich K, Duffy LA, Harlow D: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58:1097-1105, 1989.
4. 4. Cavenee WK, Dryja TP, Philips RA, et al: Expression of recessive allele by chromosomal mechanisms in retinoblastoma. Nature 305:779-784, 1983.
5. 5. Collins VP, James CD: Gene and chromosomal alterations associated with the development of human gliomas. FASEB J 7:926-930, 1993.
6. 6. Cordon-Cardo C: Mutation of cell regulators. Biological and clinical implications for human neoplasia Am J Pathol 147:545-560, 1995.
7. 7. Cordon-Cardo C, Wartinger D. Petrylak D, et al: Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84:1251-1256, 1992.
8. 8. Ellison DW, Gatter KC, Steart PV, et al: Expression of the p53 protein in a spectrum of astrocytic tumors. J Pathol 168:383-386, 1992.
9. 9. Fults D, Brockmeyer D, Tullous MW, et al: p53 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res 52:674-679, 1992.
10. 10. Haapasalo H, Isola J, Sa P, et al: Aberrant p53 expression in astrocytic neoplasma of the brain. Association with proliferation. Am J Pathol 142:1347-1351, 1993.
11. 11. Hamel W, Westphal M, Shepard HM: Loss in expression of the retinoblastoma gene product in human gliomas is associated with advanced disease. J Neuro oncology 16:159-165, 1993.
12. 12. Hansen MF, Koufos A, Gallie BL, et al: Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 82:6216-6220, 1985.
13. 13. He J, Jeffrey JO, James CD: Lack of p16 INK4 or Retinoblastoma protein (pRb) or amplification associated over expression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55:4833-4836, 1995.
14. 14. Henson JW, Schnitker BL, Lorrea KM, et al: The retinoblastoma gene is involved in malignant progression of Astrocytomas. Ann Neurol 36:714-721, 1994.
15. 15. Hesketh R: The oncogene handbook. Academic Press, California, 1994, p526.
16. 16. Ichimura K, Schmidt EE, Loike HM, et al: Human glioblastomas with an alteration of the CDKN2A (p16 INK4A, MTS1) and CDK4 gene have frequent mutations of the retinoblastoma gene. Oncogene 13:1065-1072, 1996.
17. 17. Ishikawa J, Xu H.J, Hu S-X, et al: Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 51:5736-5743, 1991.
18. 18. Iuzzolino P, Ghimenton C, Nicolato A, et al: p53 protein in low-grade astrocytomas: a study with long-term follow-up. Br J Cancer 69:586-591, 1994.
19. 19. Jahnson S, Risberg B, Korlsson MG, et al: p53 and Rb immunostaining is locally advanced bladder cancer: Relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Uro 28:135-142, 1995.
20. 20. Karpeh MS, Brennass MF, Canee WG, et al: Altered patterns of retinoblastoma gene product expression in adult soft tissue sarcomas. Br J Cancer 72:986-991, 1995.
21. 21. Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumors of the central nervous system. International classification of tumors No. 21, 2nd edn. World Health Organization, Geneva, 1993.
22. 22. Lee WH, Shew JY, Hong FD: The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 329:642-645, 1987.
23. 23. Lee SH, Kim JH, Rhee CH, et al: Loss of heterozygosity on chromosome 10, 13q (Rb), 17p and p53 gene mutations in human brain gliomas. J Korean Med Sci 10:442-448, 1995.
24. 24. Levine AJ: The tumor suppressor genes. Ann. Rev. Biochem 62:623-651, 1993.
25. 25. Louis DN, von Deimling A, Chung RY: Comparative study of p53 gene and protein alterations in human astrocytomas. J Neuropathol Exp Neurol 52:31-38, 1993.
26. 26. Mihara K, Cao X-R, Yen A, et al: Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246:1300-1303, 1982.
27. 27. Nakamura M, Konishi N, Tsunoda S, et al: Immunohistochemical evaluation of pRb, p16, INK4 and cyclin D1 as a prognostic factor in astrocytic tumors (Abst) J Neurooncol 30:111, 1996.
28. 28. Rasheed ABK, Mchendon RE, Herndon JE, et al: Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324-1330, 1994.
29. 29. Trudel M, Mulligass L, Cavenee WK, et al: Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. Human Pathol 23:388-1394, 1992.
30. 30. Tsuzuki T, Tsunoda S, Sakaki T, et al: Alterations of retinoblastoma, p53, p16 (CDKN2), and p15 genes in human astrocytomas. Cancer 78:287-293, 1996.
31. 31. Watanabe K, Tachibana O, Yonekawa Y, et al: Role of gemistocytes in astrocytoma progression. Lab Invest 76:277-284, 1997.
32. 32. Whyte P, Buchkovich KJ, Horowitz JM, et al: Association between an oncogene and an anti-oncogene: the adenovirus EIA proteins bind to the retinoblastoma gene product. Nature 334:124-129, 1988.